2-{1-[6-chloroimidazo[2,1 b][1,3]thiazol-5-yl)sulfonyl]-1H-Indol-3 yl}ethylamine compound

Abstract

The present invention provides a compound of formula I wherein wherein Q is SO2, CO, CONR9 or CSNR10; n is an integer of 2 or 3; R1 and R2 are each independently H, halogen, CN, OCO2R12, CO2R13, CONR14R15, CNR16NR17R18, SOmR19, NR20R21, OR22, COR23 or a C1-C6alkyl, C2-C6alkenyl, C2-C6a1kynyl, C3 C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R3 and R4 are each independently H or an optionally substituted C1-C6alkyl group; R5 and R6 are each independently H or a C1-C6alkyl, C2- C6alkenyl, C2-C6alkynyl, C3-C6cycloa1kyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted, or R5 and R6 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S; R7 is H, halogen, or a C1-C6alkyl, C1 C6alkoxy, aryl or heteroaryl group each optionally substituted; R8 is an optionally substituted 8- to 13 membered bicyclic or tricyclic ring system having a N atom at a abridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S; m is 0 or an integer of 1 or 2; and pharmaceutical composition comprising the compound and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5 HT6 receptor.